

Manufacturer Name	NDC	Name of Prescription Drug	Strength	Pack Size/Volume	WAC (as of date of commercial availability)	Date of Commercial Availability	Estimated volume of patients who may be prescribed drug	Breakthrough therapy designation? (Y/N)	Priority Review? (Y/N)	Date and price of acquisition if the drug was not developed by the manufacturer else N/A	A description of the marketing and pricing plans used in the launch of the new drug This drug is a generic drug and marketed in traditional generic ways through typical wholesale and chargeback channels.
Exelan Pharmaceuticals	76282-0678-30	EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DF TAB	600-200-300MG	30	\$1,599.90	4/27/2021	N/A	N	N	N/A	